A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.
Solid Tumor
DRUG: GFS101A|DRUG: Toripalimab
Phase Iï¼šIncidence of dose limiting toxicity (DLT) events, 21days|Phase II: Overall response rate (ORR) per RECIST 1.1, approximately 12 months after first dose
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.